Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition

BackgroundInflammatory responses play a multiphase role in the pathogenesis of cerebral ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. Based on its anti-inflammatory and immunosuppressive effects, we hypothesize...

Full description

Bibliographic Details
Main Authors: Hua Zhu, Zhihong Jian, Yi Zhong, Yingze Ye, Yonggang Zhang, Xinyao Hu, Bei Pu, Lijuan Gu, Xiaoxing Xiong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
ruxolitinib
ischemic stroke
neuroinflammation
NLRP3 inflammasome
JAK2/STAT3
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.714943/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.714943/full

Similar Items